A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate Cardiovascular Outcomes During Treatment With Lixisenatide in Type 2 Diabetic Patients After an Acute Coronary Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs Lixisenatide (Primary)
  • Indications Cardiovascular disorders; Coronary artery disease; Diabetic angiopathies; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms ELIXA
  • Sponsors Sanofi
  • Most Recent Events

    • 26 Jun 2018 Results of post hoc analysis of ELIXA trial presented at the 78th Annual Scientific Sessions of the American Diabetes Association
    • 01 Feb 2018 Results evaluating risk of cardiovascular events from ELIXA, LEADER, SUSTAIN-6 and EXSCEL studies, published in the Annals of Pharmacotherapy.
    • 16 Nov 2016 Results assessing the association between retinopathy and neuropathy with cardiovascular events presented at the 89th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top